EORTC Gynecological Cancer Group

Open studyStudy to be openClosed study
55116
A Phase III Randomized Trial of Gemcitabine plus Docetaxel followed by Doxorubicin v. observation for uterus-limited, High Grade Uterine Leiomyosarcoma
55092
Phase IB-II, open label, multicentre feasibility study of Pazopanib in combination with Paclitaxel and Carboplatin in patients with platinum-refractory/resistant ovarian, fallopian tube or peritoneal carcinoma.
55102
A phase III Trial of postoperative chemotherapy or no further treatment for patients with stage I-II medium or high risk endometrial cancer.
55051
A multi-national randomized Phase III GCIG Intergroup Study comparing Pegylated Liposomal Doxorubicin and Carboplatin (CaC) versus Paclitaxel and Carboplatin (TC) in patients with epithelial ovarian cancer in late relapse (>6 months).
55041
A randomized, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer
55984
A randomized trial of Adryamicin (A) Cisplatin (P) chemotherapy versus Paclitaxel (T) Adriamycin (A) and Cisplatin (P) in patients with metastatic/relapsed or locally advanced inoperable endometrial cancer.
55012
A phase III study of Cisplatin plus Topotecan followed by Paclitaxel plus Carboplatin versus Paclitaxel plus Carboplatin as first line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer.
55994
Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO Ib2, IIa > 4 cm or IIb cervical cancer.
55961
EORTC 55961,Phase II study on Paclitaxel in recurrent uterine papillary serous carcinoma (UPSC)
55005
A randomized phase III study comparing Gemcitabine plus Carboplatin versus Carboplatin monotherapy in patients with advanced eepithelial ovarian carcinoma who failed first-line platinum based therapy Intergroup AGO-EORTC-NCIC CTG trial (EORTC 55005)
55985
PHASE II CLINICAL TRIAL ON TAXOL AS SINGLE AGENT IN LOCALLY ADVANCED AND/OR METASTATIC OR RECURRENT VULVA CANCER NOT AMENABLE FOR SURGERY AND/OR RADIOTHERAPY - EORTC trial 55985
55963
A randomized phase III study for the treatment of recurrent epithelial ovarian cancer: Chemotherapy alone versus chemotherapy followed by secondary cytoreductive surgery in patients with a treatment-free interval of more than 12 months-trial 55963
55991
A randomized trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high risk endometrial carcinoma.
55981
A randomized trial of Paclitaxel/Epirubicin/Carboplatin Combination (TEC) versus Paclitaxel/Carboplatin (TC) in the treatment of women with Advanced Ovarian Cancer
55955
A randomised trial in relapsed ovarian cancer: Early treatment based on CA 125 levels alone vs Delayed treatment based on conventional clinical indicators - MRC OV05 and EORTC/GCCG 55955
55971
Randomized Phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with Stage IIIc or IV epithelial ovarian carcinoma.
55962
A randomized phase III trial for evaluation of usefullness of pelvic drains after radical hysterectomy and node dissection (RHND)
55954
A randomized phase III study of chemotherapy and radiotherapy versus radiotherapy alone as adjuvant treatment to patients with node positive stages Ib or IIa cervix cancer (EO ORTC/NSGO/COSA/MRC intergroup trial)
55951
Taxol or Oxaliplatin in platinum-pretreated advanced ovarian cancer patients
55931
EORTC-NCIC-Scottish-Scandinavian-Intergroup phase III comparison of a combination of Taxol-platinum and a combination of cyclophosphamide-platinum chemotherapy in the treatment of advanced epithelial ovarian cancer
55842
Phase II trial of 4'-epiDoxorubicin in disseminated carcinoma of the uterine cervix
55923
Phase II study of Cisplatin, Doxorubicin, and Ifosfamide in carcinosarcoma (malignant mixed mesodermal tumors) of the female genital tract
55904
Phase III study to evaluate platinum based chemotherapy as an adjuvant to surgery in early ovarian cancer patients
55883
Phase II study of Navelbine in patients with advanced and/or recurrent cervical carcinoma
55892
Phase II study of high dose Epirubicin in patients with advanced ovarian carcinoma
55891
Phase II study of etoposide in patients with recurrent or advanced granulosa-theca cell tumor of the ovary
55881
Phase II trial of Fotemustine (S 100360) in patients with advanced ovarian carcinoma
55882
PHASE II TRIAL OF FLUTAMIDE IN PATIENTS WITH ADVANCED OVARIAN CARCINOMA.
55872
Randomized phase II protocol to study adriamycin/Cisplatin in combination and adriamycin alone in patients with advanced and/or recurrent endometrial carcinoma
55874
Phase III study to evaluate the role of adjuvant radiotherapy in the treatment of uterine sarcomas stages I and II
55875
Intraperitoneal Cisplatin versus no further treatment: A phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based induction chemotherapy and cytoreductive surgery
55876
Phase II study of D-TRP-6-LHRH (decapeptyl) in patients with advanced ovarian carcinoma
55871
Phase II study of bleomycin, Methotrexate and CCNU in locally advanced, radically inoperable squamous cell carcinoma of the vulva
55873
Randomized phase II protocol to study cyclophosphamide or Ifosfamide in patients with advanced and/or recurrent endometrial carcinoma
55865
Phase III study for the treatment of ovarian cancer FIGO stages IIB and C, III and IV
55863
Randomized phase III trial of vindesine, Cisplatin, bleomycin and mitomycin-C (BEMP) versus Cisplatin (P) in disseminated squamous cell carcinoma of the uterine cervix
55862
Phase II study of a combination of cis-diammine-dichloro-platinum, vinblastine, and bleomycin in patients with recurrent or advanced dysgerminoma
55856
Phase II trial for intraperitoneal cisplatin in ovarian cancer FIGO III, IV minimal residual disease after chemotherapy and cytoreductive surgery
55857
Phase II trial of 5-aza-2'-deoxycytidine in patients with advanced or recurrent squamous cell carcinoma of the uterine cervix
55854
Phase II Randomized Chemotherapy Trial of CHIP vs CACP in Patients with Advanced Ovarian Cancer Refractory or Recurrent After First-Line Chemotherapy with CBDCA (Summary Last Modified 05/88)
55853
Phase II trial of carboplatin in advanced/recurrent endometrial carcinoma
55852
Phase II trial of a combination of Cyclophosphamide, Adriamycin, and Cisplatin (CAP) in advanced tuba carcinoma
55851
Phase II trial of a combination of vindesine, Cisplatin, bleomycin, and mitomycin-C (BEMP) in disseminated squamous cell carcinoma of the uterine cervix
55843
Phase II trial of a combination of cis-diammine-dichloro-platinum, vinblastine, and bleomycin in patients with recurrent or advanced granulosa-theca cell tumors of the ovary
55839
Phase II Chemotherapy with Mitoxantrone for Recurrent and/or Disseminated Endometrial Carcinoma
55831
Phase II study of bleomycin, methotrexate, and CCNU in advanced radically inoperable squamous cell carcinoma of the vulva
55832
Phase II study of mitomycin C - cisplatin in disseminated squamous cell carcinoma of the uterine cervix
55835
Phase II study of bromocriptine in the treatment of patients with carcinoma of the cervix
55837
Phase II study of 4'-deoxydoxorubicin in patients with advanced ovarian carcinoma
55838
Phase II study of tamoxifen in patients with advanced ovarian carcinoma
55833
Phase II study of cyclophosphamide, adriamycin and cis-diammine-dichloroplatinum (II) in disseminated endometrial carcinoma.
55836
Phase III study for the treatment of ovarian cancer FIGO IIb, c, III and IV.
55845
Phase II study of 1, 2, 4-triglycidylurazol (TGU) in patients with advanced ovarian carcinoma
55858
Phase II trial of high dose megestrol acetate in patients with advanced ovarian carcinoma
55804
Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer
55811
Phase II trial of vindesine in disseminated cancer of the uterine cervix
55774
Treatment of stage III and IV ovarian cancer with VP-16 213 (phase II study)
55861
Phase II study of mitozolomide in patients with advanced ovarian carcinoma
55773
Phase III trial of melphalan versus adriamycin plus CTX in stage IC, IIB, III and IV epithelial carcinoma of the ovary
55775
Phase II study of bleomycin infusion in advanced ovarian cancer
55781
Phase III trial of cyclophosphamide plus adriamycin versus cyclophosphamide plus adriamycin plus cisplatin in stage III and IV epithelial carcinoma of the ovary
55802
Phase II trial of vincristine, bleomycin, mitomycin C and cisplatin in disseminated squamous cell carcinoma of the uterine cervix
55803
Phase II trial of PALA in advanced ovarian cancer
55771
Randomized controlled clinical trial (in progress jointly with the Ovary Group) for the treatment of patients with stages IA 2, IB, IIA: surgery followed by radiotherapy to the pelvis followed by a randomization between melphalan maintenance chemotherapy (12 months) and no further treatment
55772
Randomized controlled clinical trial (in progress jointly with the Ovary Group) for the treatment of patients with stages IC, IIB, III (< 2 cm residual disease) : surgery followed by a randomization between abdominal pelvic irradiation and no irradiation; both followed by melphalan maintenance chemotherapy (12 months)
62113
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment
1212
A Randomised Phase II Study of BIBF 1120 compared to Chemotherapy in Patients with Recurrent Clear Cell Carcinoma of the Ovary or Endometrium

Back to Group-list